pharma · Chronic Spontaneous Urticaria · Asthma
Novartis India
Novartis Pharmaceuticals
Novartis Pharmaceuticals is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Spontaneous Urticaria, Asthma, Systemic Lupus Erythematosus, Breast Cancer, Multiple Sclerosis. NovaP
Mumbai, IN HQ
1996 Founded
2,240 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Mumbai, IN
- Founded
- 1996
- Employees
- 2,240
- Programs
- 341
- Drugs
- 317
- Patents
- 0
CIDH305X2101
Phase 1 · other · Advanced malignancies that harbor IDH1R132 mutations
CIDH305X2101 for Advanced malignancies that harbor IDH1R132 mutations is a Phase 1 program (other) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code CIDH305X2101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 1
- Modality
- other
- Indication
- Advanced malignancies that harbor IDH1R132 mutations
- Status
- active
- Trials
- 1